Shares of Amicus Therapeutics (NASDAQ: FOLD) surged 5.87% in pre-market trading on Thursday, following the release of the company's second-quarter 2025 financial results that significantly exceeded analyst expectations. The biotechnology firm, focused on developing treatments for rare metabolic diseases, delivered a strong performance that underscores its growth trajectory and improving financial health.

Amicus reported an adjusted earnings per share (EPS) of $0.01, dramatically outperforming the analyst consensus estimate of -$0.11. This represents a remarkable 109.09% beat and showcases the company's progress towards profitability. Revenue for the quarter came in at $154.688 million, surpassing the projected $147.399 million and marking a robust 22.12% increase from the same period last year.

The company's strong quarterly performance was accompanied by an optimistic outlook. Amicus Therapeutics stated it is "firmly positioned to reach GAAP profitability in H2 2025," a milestone that investors are clearly excited about. Additionally, management reiterated its 2025 financial guidance, further boosting confidence in the company's near-term prospects. With these positive developments, Amicus Therapeutics continues to demonstrate its potential in the competitive biotechnology sector, driving investor enthusiasm and the subsequent pre-market stock surge.